ES2029829T3 - Un procedimiento para la preparacion de compuestos antihipercolesterolemicos. - Google Patents

Un procedimiento para la preparacion de compuestos antihipercolesterolemicos.

Info

Publication number
ES2029829T3
ES2029829T3 ES198787300544T ES87300544T ES2029829T3 ES 2029829 T3 ES2029829 T3 ES 2029829T3 ES 198787300544 T ES198787300544 T ES 198787300544T ES 87300544 T ES87300544 T ES 87300544T ES 2029829 T3 ES2029829 T3 ES 2029829T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
compounds
hypercholesterolemic
hypercholesterolemic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787300544T
Other languages
English (en)
Inventor
Robert L. Smith
Gerald E. Stokker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2029829T3 publication Critical patent/ES2029829T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBEN NUEVOS INHIBIDORES DE LA 3-HIDROXI-3- METIL-GLUTARIL-COENZIMA A(HMG-COA)REDUCTASA QUE SON UTILES COMO AGENTES ANTIHIPERCOLESTEROLEMICOS Y ESTAN REPRESENTADOS POR LAS SIGUIENTES FORMULAS ESTRUCTURALES (I) Y (II). SE DESCRIBEN TAMBIEN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS COMPUESTOS (II) EN DONDE Z ES HIDROGENO.
ES198787300544T 1986-01-31 1987-01-22 Un procedimiento para la preparacion de compuestos antihipercolesterolemicos. Expired - Lifetime ES2029829T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/824,900 US4772626A (en) 1986-01-31 1986-01-31 Antihypercholesterolemic compounds

Publications (1)

Publication Number Publication Date
ES2029829T3 true ES2029829T3 (es) 1992-10-01

Family

ID=25242603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787300544T Expired - Lifetime ES2029829T3 (es) 1986-01-31 1987-01-22 Un procedimiento para la preparacion de compuestos antihipercolesterolemicos.

Country Status (7)

Country Link
US (1) US4772626A (es)
EP (1) EP0232997B1 (es)
JP (1) JPS62190144A (es)
AT (1) ATE56715T1 (es)
DE (1) DE3764967D1 (es)
DK (1) DK51087A (es)
ES (1) ES2029829T3 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855321A (en) * 1986-01-31 1989-08-08 Merck & Co., Inc. Antihypercholesterolemic compounds
US5169976A (en) * 1987-11-25 1992-12-08 Pfizer Inc. N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents
US4904691A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US5001144A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5001128A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4863957A (en) * 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4939143A (en) * 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4876280A (en) * 1988-03-10 1989-10-24 Sandoz Pharm. Corp. Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use
DE3818570A1 (de) * 1988-06-01 1989-12-21 Boehringer Mannheim Gmbh Neue 6-substituierte-4-hydroxy-tetrahydro-pyran -2-on-derivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
DE3909378A1 (de) * 1989-03-22 1990-09-27 Bayer Ag Substituierte biphenyle
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5149834A (en) * 1990-03-07 1992-09-22 Fujirebio Inc. 4-hydroxytetrahydropyran-2-one derivatives
WO1991013616A1 (en) * 1990-03-08 1991-09-19 Rorer International (Overseas) Inc. NOVEL HMG-CoA REDUCTASE INHIBITORS
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids
HUE037395T2 (hu) * 2007-05-29 2018-08-28 Evonik Degussa Gmbh Aktivált alapfém katalizátorok
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459422A (en) * 1979-08-17 1984-07-10 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4567289A (en) * 1979-08-17 1986-01-28 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis

Also Published As

Publication number Publication date
DK51087D0 (da) 1987-01-30
EP0232997B1 (en) 1990-09-19
DK51087A (da) 1987-08-01
DE3764967D1 (de) 1990-10-25
EP0232997A1 (en) 1987-08-19
JPS62190144A (ja) 1987-08-20
ATE56715T1 (de) 1990-10-15
US4772626A (en) 1988-09-20

Similar Documents

Publication Publication Date Title
ES2029829T3 (es) Un procedimiento para la preparacion de compuestos antihipercolesterolemicos.
AR003401A1 (es) Procedimiento para la peparacion de sildenafil y compuestos intermediarios para dicho procedimiento
ES2053582T3 (es) Procedimiento para la obtencion de derivados del acido 5-amino-4-hidroxivalerianico.
ES2055056T3 (es) Derivados de pirimidopirimidina.
AR038430A2 (es) Derivados de parahercuamida b
ES2062395T3 (es) Nuevos compuestos de bencimidazol y su uso.
ES2033840T3 (es) P-aminoetilsulfonanilidas n-sustituidas como agentes antiarritmicos; e intermedios para los mismos.
CO4920223A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8- sustituidos
ES2159738T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
UY24625A1 (es) Derivados de la 4-hidroxi-piperidina
ES2048109A1 (es) Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
ES2059724T3 (es) Un procedimiento para preparar derivados de purinil piperacina 6-sustituidos.
ES2061451T3 (es) Derivados de trans-6-(2-(n-heteroaril-3,5-disubstituido)pirazol-4-il)-etil)- o etenil)tetrahidro-4-hidroxipiran-2-ona, un proceso para su preparacion y uso de los mismos.
ES2040879T3 (es) Procedimiento de preparacion de derivados pirimidinilaminicos de piperidina.
ES2123873T3 (es) Pirrolocarbazol.
ES2061580T3 (es) Compuestos de 3,7-diazabiciclo(3,3,1)nonano, asi como procedimiento para su preparacion y medicamentos que contienen estos compuestos.
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
ES470787A1 (es) Procedimiento para preparar derivados de benzoquinolicina
MX9300361A (es) Derivado de 4-aril-3-heteroarilureidoquinolina como agentes antihipercolesterolemicos y antiateroscleroticos.
AR004780A1 (es) Derivados de 2-tioxo-imidazolidin-4-ona
MX9303933A (es) Compuestos intermedios sinteticos novedosos y procedimiento para la preparacion de los derivados de los aminoacidos.
ES2182090T3 (es) Nuevos derivados de pirrol.
ES2008109B3 (es) Procedimiento de preparacion de aminoalcoholes y de composiciones farmaceuticas que los contienen.
ES2075180T3 (es) Nuevos derivados de la piridona, su procedimiento de preparacion, los nuevos productos intermedios obtenidos, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
ES2037770T3 (es) Procedimiento para la preparacion de intermediarios para la sintesis de fosfomicina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 232997

Country of ref document: ES